Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 917945, 10 pages
http://dx.doi.org/10.1155/2015/917945
Research Article

Inhibition of TNF-α Reverses the Pathological Resorption Pit Profile of Osteoclasts from Patients with Acute Charcot Osteoarthropathy

1Diabetic Foot Clinic, King’s College Hospital, London SE5 9RS, UK
2Department of Materials, Imperial College London, London SW7 2AZ, UK
3Cardiovascular Division, King’s College London, London SE5 9NU, UK

Received 12 February 2015; Revised 23 April 2015; Accepted 23 April 2015

Academic Editor: Andrea Scaramuzza

Copyright © 2015 Nina L. Petrova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. L. Petrova and M. E. Edmonds, “Charcot neuro-osteoarthropathy—current standards,” Diabetes/Metabolism Research and Reviews, vol. 24, supplement 1, pp. S58–S61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Gazis, N. Pound, R. Macfarlane, K. Treece, F. Game, and W. Jeffcoate, “Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot),” Diabetic Medicine, vol. 21, no. 11, pp. 1243–1246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. van Baal, R. Hubbard, F. Game, and W. Jeffcoate, “Mortality associated with acute charcot foot and neuropathic foot ulceration,” Diabetes Care, vol. 33, no. 5, pp. 1086–1089, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M.-W. Sohn, T. A. Lee, R. M. Stuck, R. G. Frykberg, and E. Budiman-Mak, “Mortality risk of charcot arthropathy compared with that of diabetic foot ulcer and diabetes alone,” Diabetes Care, vol. 32, no. 5, pp. 816–821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. C. Rogers, R. G. Frykberg, D. G. Armstrong et al., “The Charcot foot in diabetes,” Diabetes Care, vol. 34, no. 9, pp. 2123–2129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Jeffcoate, F. Game, and P. R. Cavanagh, “The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes,” The Lancet, vol. 366, no. 9502, pp. 2058–2061, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Mabilleau, N. L. Petrova, M. E. Edmonds, and A. Sabokbar, “Increased osteoclastic activity in acute Charcot's osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand,” Diabetologia, vol. 51, no. 6, pp. 1035–1040, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. N. L. Petrova, P. K. Petrov, M. E. Edmonds, and C. M. Shanahan, “Novel use of a Dektak 150 surface profiler unmasks differences in resorption pit profiles between control and Charcot patient osteoclasts,” Calcified Tissue International, vol. 94, no. 4, pp. 403–411, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Lam, Y. Abu-Amer, C. A. Nelson, D. H. Fremont, F. P. Ross, and S. L. Teitelbaum, “Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis,” Annals of the Rheumatic Diseases, vol. 61, no. 2, pp. ii82–ii83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Romas, “Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates,” Best Practice and Research: Clinical Rheumatology, vol. 19, no. 6, pp. 1065–1079, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. C. Walsh and E. M. Gravallese, “Bone loss in inflammatory arthritis: mechanisms and treatment strategies,” Current Opinion in Rheumatology, vol. 16, no. 4, pp. 419–427, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. T. Ritchlin, S. A. Haas-Smith, P. Li, D. G. Hicks, and E. M. Schwarz, “Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis,” Journal of Clinical Investigation, vol. 111, no. 6, pp. 821–831, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Redlich and J. S. Smolen, “Inflammatory bone loss: pathogenesis and therapeutic intervention,” Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 234–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. P. Cope, M. Londei, N. R. Chu et al., “Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis,” The Journal of Clinical Investigation, vol. 94, no. 2, pp. 749–760, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Tanaka, N. Takahashi, N. Udagawa et al., “Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors,” The Journal of Clinical Investigation, vol. 91, no. 1, pp. 257–263, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Yasuda, N. Shima, N. Nakagawa et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3597–3602, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. Teitelbaum, “Osteoclasts: what do they do and how do they do it?” American Journal of Pathology, vol. 170, no. 2, pp. 427–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Henriksen, J. Bollerslev, V. Everts, and M. A. Karsdal, “Osteoclast activity and subtypes as a function of physiology and pathology—implications for future treatments of osteoporosis,” Endocrine Reviews, vol. 32, no. 1, pp. 31–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Jirkovská, P. Kasalický, P. Bouček, J. Hosová, and J. Skibová, “Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover,” Diabetic Medicine, vol. 18, no. 6, pp. 495–500, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. N. L. Petrova, A. V. M. Foster, and M. E. Edmonds, “Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between Type 1 and Type 2 diabetes,” Diabetic Medicine, vol. 22, no. 6, pp. 756–761, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. F. Baumhauer, R. J. O'Keefe, L. C. Schon, and M. S. Pinzur, “Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study,” Foot & Ankle International, vol. 27, no. 10, pp. 797–800, 2006. View at Google Scholar · View at Scopus
  22. N. L. Petrova, T. K. Dew, R. L. Musto et al., “Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy,” Diabetic Medicine, vol. 32, no. 2, pp. 267–273, 2015. View at Publisher · View at Google Scholar
  23. L. Uccioli, A. Sinistro, C. Almerighi et al., “Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot,” Diabetes Care, vol. 33, no. 2, pp. 350–355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers, “TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL,” Endocrinology, vol. 143, no. 3, pp. 1108–1118, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Søe, D. M. H. Merrild, and J.-M. Delaissé, “Steering the osteoclast through the demineralization-collagenolysis balance,” Bone, vol. 56, no. 1, pp. 191–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. B. R. Troen, “The regulation of cathepsin K gene expression,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 165–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. T. Johnson, “Neuropathic fractures and joint injuries. Pathogenesis and rationale of prevention and treatment,” The Journal of Bone & Joint Surgery—American Volume, vol. 49, no. 1, pp. 1–30, 1967. View at Google Scholar · View at Scopus
  28. T. J. Heino, K. Kurata, H. Higaki, and H. K. Väänänen, “Evidence for the role of osteocytes in the initiation of targeted remodeling,” Technology and Health Care, vol. 17, no. 1, pp. 49–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Kon, T.-J. Cho, T. Aizawa et al., “Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing,” Journal of Bone and Mineral Research, vol. 16, no. 6, pp. 1004–1014, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. N. W. A. McGowan, E. J. Walker, H. Macpherson, S. H. Ralston, and M. H. Helfrich, “Cytokine-activated endothelium recruits osteoclast precursors,” Endocrinology, vol. 142, no. 4, pp. 1678–1681, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. B. A. Mosheimer, N. C. Kaneider, C. Feistritzer, D. H. Sturn, and C. J. Wiedermann, “Expression and function of RANK in human monocyte chemotaxis,” Arthritis & Rheumatism, vol. 50, no. 7, pp. 2309–2316, 2004. View at Publisher · View at Google Scholar · View at Scopus